がん臨床試験ジャーナル

Tumor Mutational Burden and its Association with Immunotherapy Response in Different Solid Tumor Types and Regimens: Retrospective Study in Solid Tumors at the Beverly Hills Cancer Center

Abstract

Amir Pirooz, MD, Aaron Gabayan, Yousuf Altameemi and Ali Muhammad, MD, MBA*

Our providers’ continuous efforts to obtain NGS testing for their cancer patients as early as possible followed by matched therapy has provided new therapeutic options to our solid tumor patients. We report our experience here with this approach in everyday clinical practice at the Beverly Hills Cancer Center along with our robust clinical research program. This retrospective study included 31 solid tumor patients who were genotyped with the FDA-approved Guardant360 CDx liquid biopsy test that provides comprehensive genomic results from a blood draw in seven days. Our oncologists use this on a regular basis for tumor mutation profiling, also known as Comprehensive Genomic Profiling (CGP), across all solid cancers. The goal was to better define the association between the level of TMB expression and response to immunotherapy.